Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer. 

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer 

Shubham Pant, MD, MBBS, discusses findings from the phase 2b HERIZON-BTC-01 study of zanidatamab in pretreated HER2-positive biliary tract cancer.

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

RAS-Directed Therapy and Patient Selection Are Sectors to Watch in Pancreatic Cancer 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

My Treatment Approach: Targeting Genetic Alterations in Tumors: Clinical Scenarios and Precision Oncology Approaches

Clinical

Video Series

BRAF V600E Mutant Ganglioglioma

Videos

Insights into integrating tumor agnostic therapies for actionable genetic alterations across solid tumors. Renowned experts Dr. Vivek Subbiah, Dr. Karisa Schreck, and Dr. Rimas Lukas delve into pivotal clinical cases showcasing the identification and targeted treatment of BRAF and RET fusions. The in-depth discussion spotlights practical strategies for NGS testing, overcoming barriers to adoption, efficacy and safety data from landmark trials, sequencing of therapies, and the evolving landscape of precision oncology beyond current approvals. Gain invaluable clinical pearls for optimizing patient outcomes with tumor agnostic targeted agents in the community setting.

Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing. 

Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors 

Dr. Lukas presents a case of a young man with a BRAF-fused brain tumor treated with a MEK inhibitor. Explored tailored therapy targeting the underlying genetic alteration. 

Targeting RET Fusion in Brain Tumor

Dr. Schreck brings forward a compelling case of a teenage female with BRAF V600E mutant ganglioglioma. Witness how the identification of this specific genetic alteration paved the way for treated with targeted therapy.

BRAF V600E Mutant Ganglioglioma 

Experts discuss the challenges in adopting targeted therapies like BRAF/MEK inhibitors for BRAF-altered gliomas and gangliogliomas and strategies to facilitate their integration into practice.

Challenges in Adopting Targeted Therapies for BRAF Alterations

Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.

Efficacy and Safety of Tumor Agnostic Therapies  

Dr. Subbiah presents a pancreatic cancer case with PRKARA1A- RET fusion treated with selpercatinib in a clinical trial. 

PRKAR1A-RET Fusion in Pancreatic Cancer: Unlocking New Therapeutic Frontiers 

The panel discusses the impact of tumor agnostic approvals like BRAF/MEK inhibitors on the treatment landscape, unmet needs address and sequencing therapies like RET inhibitors in cancers like pancreatic cancer. 

Impact and Positioning of Tumor Agnostic Approvals  

The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer. 

Future Outlook for RET Fusion-Targeted Therapies 

BRAF V600E Mutant Ganglioglioma

EP: 1.Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors

EP: 2.Targeting RET Fusion in Brain Tumor

EP: 3.BRAF V600E Mutant Ganglioglioma

EP: 4.Challenges in Adopting Targeted Therapies for BRAF Alterations

EP: 5.Efficacy and Safety of Tumor Agnostic Therapies

EP: 6.PRKAR1A-RET Fusion in Pancreatic Cancer: Unlocking New Therapeutic Frontiers

EP: 7.Impact and Positioning of Tumor Agnostic Approvals

EP: 8.Future Outlook for RET Fusion-Targeted Therapies

Latest Conference Coverage